The FDA won’t be issuing a controversial final rule on label changes concerning generic drug safety any time soon.
Under the rule, generic drug manufacturers would be able to independently update product labeling with newly acquired safety information before the Food and Drug Administration’s review of the change, in the same way brand drug manufacturers do. Generic manufacturers also would be required to inform the brand name manufacturer about the change under the rule, which was proposed (RIN:0910-AG94) in 2013.
Currently, FDA regulations do not permit generic drug manufacturers to update product labeling unless they are mimicking a change already made by a brand-name drug manufacturer or the FDA orders them to do so. If the rule were to go into effect, it could open the generic drug industry up to more lawsuits. Currently, generic companies can’t be sued for defects in warning labels because they can’t independently change their own labels.
The rule didn’t make it onto the Office of Management and Budget’s unified regulatory agenda released July 20. The unified agenda generally lists regulatory activities that are planned to take place within the next 12 months. The rule has been delayed several times, and the FDA had previously said it planned to issue the rule in April.
The generic drug industry wants to rule to be permanently withdrawn.
Allen Goldberg, vice president of communications for the Association for Accessible Medicines, told me the proposed version of the rule goes against the sameness requirement in the Hatch-Waxman Act and his group will continue to push for the rule to be withdrawn. The Hatch-Waxman Act, which governs the approval of generic drugs, requires brand and generic drug labels to be the same.
But the FDA is still planning to issue the final rule at some point. Jennifer Corbett Dooren, a spokeswoman for the FDA, told me that just because the rule was removed from the unified agenda, doesn’t mean the agency won’t consider it moving forward. She said the unified agenda just reflects the agency’s most immediate priorities.
Read my full article here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)